For a blood-borne cancer therapeutic agent to be effective, it must cross the blood vessel
wall to reach cancer cells in adequate quantities, and it must overcome the resistance …

The protective blood–brain barrier has a major role in ensuring normal brain function by
severely limiting and tightly controlling the ingress of substances into the brain from the …

We designed a unique nanocapsule for efficient single CRISPR-Cas9 capsuling,
noninvasive brain delivery and tumor cell targeting, demonstrating an effective and safe …

Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …

Brain metastases are a very common manifestation of cancer that have historically been
approached as a single disease entity given the uniform association with poor clinical …

Malignant brain tumors, a heterogeneous group of primary and metastatic neoplasms in the
central nervous system (CNS), are notorious for their highly invasive and devastating …

The blood-brain barrier (BBB) is an important factor limiting the effectiveness of central
nervous system (CNS) therapeutics. MR-guided focused ultrasound (MRgFUS) is a …

Microbubble-enhanced ultrasound provides a noninvasive physical method to locally
overcome major obstacles to the accumulation of blood-borne therapeutics in the brain …

Abstract Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics
combining monoclonal antibodies with a cytotoxic payload via a chemical linker, have …

Existing drug delivery methods have not led to a significant increase in survival for patients
with malignant primary brain tumors. While the combination of conventional therapies …